EINSTEIN-PE
2012
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
In 4,832 patients with acute symptomatic pulmonary embolism, single-drug oral rivaroxaban was non-inferior for recurrent venous thromboembolism and halved major bleeding compared with enoxaparin followed by a vitamin K antagonist.
Result
Efficacy: Symptomatic recurrent venous thromboembolismHR 1.12 (95% CI 0.75-1.68) · P = 0.003
Safety: Major bleedingHR 0.49 (95% CI 0.31-0.79) · P = 0.003
Below 1 favours single-drug oral rivaroxaban, above 1 favours enoxaparin followed by a vitamin K antagonist.
Event rates Single-drug oral rivaroxaban 2.1% vs enoxaparin followed by a vitamin K antagonist 1.8% (symptomatic recurrent venous thromboembolism)
- Subtopic
- Pulmonary embolism
- Design
- Open-label, event-driven non-inferiority RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ESC 2019 Pulmonary Embolism
- Source
- The EINSTEIN-PE Investigators. N Engl J Med. 2012;366(14):1287-1297.doi 10.1056/NEJMoa1113572
Discussion & critique
Open-label, and haemodynamically unstable patients were excluded, so it says nothing about high-risk PE. It is the trial that made a single-drug oral regimen with no parenteral lead-in possible and, with major bleeding halved, drives the preference for a DOAC over a VKA.